REL has been the subject of several other reports. Societe Generale reaffirmed a buy rating and set a GBX 1,840 ($24.04) price objective on shares of Relx in a research report on Friday, January 25th. Liberum Capital reiterated a buy rating on shares of Relx in a research note on Friday, March 1st. UBS Group reiterated a sell rating on shares of Relx in a research note on Monday, March 4th. Deutsche Bank reiterated a hold rating on shares of Relx in a research note on Friday, February 22nd. Finally, Goldman Sachs Group lifted their price objective on shares of Relx from GBX 2,006 ($26.21) to GBX 2,167 ($28.32) and gave the company a buy rating in a research note on Monday, January 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of GBX 1,788.08 ($23.36).
REL stock traded up GBX 20.50 ($0.27) during midday trading on Monday, hitting GBX 1,726 ($22.55). The company’s stock had a trading volume of 3,205,332 shares, compared to its average volume of 4,990,000. The stock has a market capitalization of $33.62 billion and a PE ratio of 24.17. Relx has a 52-week low of GBX 1,466.50 ($19.16) and a 52-week high of GBX 1,781.50 ($23.28). The company has a quick ratio of 0.36, a current ratio of 0.44 and a debt-to-equity ratio of 270.50.
In other Relx news, insider Erik Engstrom sold 36,334 shares of the company’s stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of GBX 1,770 ($23.13), for a total value of £643,111.80 ($840,339.47). Also, insider Henry Udow sold 50,831 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of GBX 1,759 ($22.98), for a total transaction of £894,117.29 ($1,168,322.61).
Relx Company Profile
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
See Also: Why do company’s buyback their stock?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.